4.28.23-Korea-Decoy-Therapeutics

RICK PIERCE: Good morning, and it's an honor to present to all of you. Decoy Therapeutics was founded on the work of Dr. Brad Pentelute, who you all notice today. He's in a light blue suit, so you can't miss him. We have endeavored to build what Dr. Collins basically just outlined is a platform to make peptide conjugates.

And the team that we've recruited of co-founders stems from big companies and small companies, and from the labs of people like Dr. Bob Langer at MIT, and from Brad's lab at MIT. And so we're focused on aberrant biological activities which regulate most disease states. And peptides are a unique opportunity to go after these disease states because they are highly tunable, highly specific. They are cost-effective, less toxic. And we can use them both extracellularly and intracellularly.

So Decoy has currently created a platform that can address antivirals, cancer, autoimmune, and diabetes using alpha helical structures or conjugated peptides. We have a program that has already been funded by the European Union for the Phase I and Phase II clinical trials for antivirals. And we're also funded by the Bill and Melinda Gates Foundation and work with BARDA and Johnson & Johnson.

So many of you may recognize these names on the screen. They're all peptide conjugates. They're doing billions of dollars in sales. And Eli Lilly's new drug is projected to do many more billions. Decoy's drugs work with the same chemistry as these drugs you just saw.

They use a targeting lipid tail, a linker system that's proprietary that Brad has invented many of these linkers, and warheads, which can be traditional drugs or they can be new compounds, but they can be peptides, oligos, small molecules, you name it. And we can use AI and machine learning to be able to inform us to design these drugs very quickly. So we do this using computational chemistry, a linker library that's proprietary, rapid synthesis. Brad is the inventor of the fastest peptide synthesizer, continuous flow synthesizer, in the world.

And then with partners, like you in the room, using your assays we can test after building and designing. So we now have the capability of using computational work like Dr. Collins talked about. And we can print out peptide conjugates in a matter of days. We recently made a panparamyxovirus inhibitor in three days that was picomolar and nanomolar in terms of accuracy, so lead quality drugs.

We have programs that are available for partnering. We also are looking for early discovery drug partnerships in cancer, autoimmune, as well as nose to brain drug delivery. So this would include early drug discovery as well as clinical development partners and manufacturing.

So we're located in New York City. We have a lab with JLABS and Johnson & Johnson, and we also have offices in Cambridge, Massachusetts in Kendall Square. And if any of you are interested in talking to us about partnerships for manufacturing, early drug discovery, we would love to talk to you. I'll be here today. And certainly Dr. Pentelute will be here. And if you haven't met him, you should definitely talk to him. Thank you.